MetaVia Inc. (MTVA)
1.56
0.02 (1.30%)
At close: Mar 31, 2025, 10:56 AM
1.30% (1D)
| Bid | 1.52 |
| Market Cap | 13.5M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.56 |
| PE Ratio (ttm) | -0.44 |
| Forward PE | -0.76 |
| Analyst | Buy |
| Ask | 1.65 |
| Volume | 1,868 |
| Avg. Volume (20D) | 36,096 |
| Open | 1.52 |
| Previous Close | 1.54 |
| Day's Range | 1.52 - 1.58 |
| 52-Week Range | 1.29 - 5.30 |
| Beta | 0.27 |
About MTVA
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of ...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 5, 2016
Employees 9
Stock Exchange NASDAQ
Ticker Symbol MTVA
Website https://www.metaviatx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for MTVA stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 669.23% from the latest price.
Stock Forecasts